Generic Biotechs, on the Horizon, May Spur New Wave of R&D Spending--But Can Genomics Firms Survive the Wait? | GenomeWeb

NEW YORK, Sept. 18 - A politically charged idea gaining momentum in the generic-pharmaceuticals industry may give rise to a new breed of genomic-tool and -technology customers and create a fresh wave of R&D spending, experts believe.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.